The test of your character is what it takes to stop you!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If I could predict the future I'd be the richest person on the planet. $GTBP has the potential to get there and beyond. I'm a trader and if it doubles from here I'll be happy and move on.
Immuno Oncology is the Future of Cancer Treatment! Whats wrong with being more effective and more inline with the bodies own immune system response than tradition chemotherapy? Absolutely nothing!
GTBP is on the right track in the right sector. Very good for investors.
Check out this article: https://blog.proclinical.com/uncovering-the-future-of-immuno-oncology-cancer-therapies
Here's my recap from the $GTBP CC: They built an all-star management team with big pharma experience which is huge for the company's future!
OTX -1550 immuno oncology drug is currently in phase 2 testing after strong early results. Now we are looking for phase 2 results to be released in second half of 2018. $GTBP
Read it. $GTBP has Approved FDA IND Transfer of Its First TriKE (OXS-3550) http://biotechstocks.com/gt-biopharma-inc-gtbp-announces-approved-fda-ind-transfer-of-its-first-trike-oxs-3550/ … via @Biotech Stocks
I think the real value in this company is in OXS-3550 $GTBP
OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.
OXS-3550 TRiKe looks even more promising than OXS-1550
http://bispecific.com/wp-content/uploads/sites/90/2016/10/Vallera-TRiKEs.pdf
https://ash.confex.com/ash/2016/webprogram/Paper93724.html
http://stm.sciencemag.org/content/8/328/328ec35
This is great news, running up!!!
Good to see you Blockchain!!!
This biotech stock is going back to its home at $2.00 and above. I cant name one OTC to make it to the big boards this year. After the DD I've done , Thats where $GTBP is going IMHO and is to doing everything need to get there. Long hold adding on dip.
Starting to Push higher highs 1.64 .. Plus new announcement today regarding OXS-3550 IND FILING. All over the BIOtech scanners Daily...
GT Biopharma soon will turn into a leading player in the biotechnology industry. I expect this 2018 to be a similarly productive year as compared to 2017 but with more of an emphasis on creating shareholder value by hitting our clinical and pre-clinical milestones vs reducing debt and recruiting management. I' pretty sure $GTBP will be listed on NASDAQ and will appoint additional experienced employees and board members.
[
Same here hopefully we see a continuation of yesterdays momentum. I will be keeping my eye out for that break 1.70
Yeah...let $GTBP closing the day strong pushin towards $1.70
$GTBP biotech advisors already on board: they are highly experienced and the best on their field ... would you be surprised if/when GT Biopharma starts getting real attention from some of these large biotechnology companies.
I did my homework about the new $GTBP President & CMO.
Dr. Urbanski oversee development of key products in GT Biopharma's product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies as well as its newly acquired Central Nervous System pipeline.
Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products.
He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremelimumab.
In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
He is the right guy to lead this company!!!
Dr.Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company https://biotechstocks.com/gt-biopharma-inc-gtbp-announces-dr-raymond-w-urbanski-elevated-to-president-and-chief-medical-officer-of-the-company/ … via @Biotech Stocks | Biotechnology Investments and News. The Future of Innovation & Discovery.
OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.
The consistent volume $GTBP is having makes me feel like this push past 1.70 is on its way just my opinion of course but looking at their trading pattern last time it was trending at this level it ended up running to 2.25
Awesome, lets make some profit on this undervalued Biotech in the Cancer Space...
GTBP just as I was thinking strong Intra day bounce from 1.59 to 1.65... Don't miss More Potential Moves here
I like where this company is heading, floating right under the 20 day MA. Once we see a break confirmation at that 1.70 level we should be clear skies. Considering the small float.
IMO it's a good volume day for GTBP
Hopefully breakout wow all the way to 1.70 $GTBP I am very Impressed.
Finally hit 1.60 nice move today so far everyone!
Agreed! Immuno-oncology is the next big thing for big pharma! Now, biopharmaceutical companies such as $GTBP are making dramatic advances in an emerging area of research known as immuno-oncology. This marks a significant milestone in the battle against cancer. As the name implies, immuno-oncology marshals the human body’s own immune system to fight cancer. In many cases, immunotherapy is vastly preferable to conventional treatments. Survival rates are higher in several tumor types, and these medications have the potential to significantly extend lives. Treatments also can be deployed against a wide array of cancers. I believe immuno-oncology holds enormous promise for patients and significant opportunities for investors.
Immuno-Oncology is different from surgery, radiation, and chemotherapy. Immuno-Oncology is a unique approach that uses the body's immune system to help fight cancer. If your body is like a garden, you and your healthcare team will decide on how to remove the weeds (cancer cells) while doing the least damage to the good plants (healthy cells). This garden analogy is shown below to help explain this concept
Nice move on $GTBP new hod one step closer to 1.60
Your welcome, NYC!!!
$GTBP has Approved FDA IND Transfer of Its First TriKE (OXS-3550) http://biotechstocks.com/gt-biopharma-inc-gtbp-announces-approved-fda-ind-transfer-of-its-first-trike-oxs-3550/ … via @Biotech Stocks
I think the real value in this company is in OXS-3550 $GTBP
OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.
OXS-3550 TRiKe looks even more promising than OXS-1550
http://bispecific.com/wp-content/uploads/sites/90/2016/10/Vallera-TRiKEs.pdf
https://ash.confex.com/ash/2016/webprogram/Paper93724.html
http://stm.sciencemag.org/content/8/328/328ec35
Morning everyone!!!
Good morning $ADAC friends
IMHO GT Biopharma soon will turn into a leading player in the biotechnology industry. I expect this 2018 to be a similarly productive year as compared to 2017 but with more of an emphasis on creating shareholder value by hitting our clinical and pre-clinical milestones vs reducing debt and recruiting management. I' pretty sure $GTBP will be listed on NASDAQ and will appoint additional experienced employees and board members.
Immuno Oncology is to cancer what smart bombs are to terrorists. It drops a Hellfire missile in the bad guy's lap without damaging the school next door. No collateral damage. The therapy can be calibrated to go only after the cancer cells or cancer stem cells, without damaging healthy cells. It can harness the bodies own "killer cells" to go after cancer cells and deliver deadly "payloads" to those malignant cells alone. This is a huge win not only against cancer, but for the dignity and quality of human life in the midst of medical treatment. It is not just a medicine, it is a victory for humanity.
or you can say Immuno Oncology is to traditional chemo what UBER was to traditional TAXI and: the future has arrived.
Immuno-oncology, one of the pillars of cancer treatment, is driving engagement worldwide among biotech, large pharma, universities/cancer centers and the financial investment community. Currently, more than 130 biotech and 20 pharma companies are developing immuno-oncology therapies and GT Biopharma is one of a leading pharma company! $GTBP